ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in the NOK 370 million IPO of Ultimovacs ASA

Ultimovacs ASA (”Ultimovacs”) announced on Wednesday 29 May the successful completion of its
initial public offering (the “IPO”) with trading on Oslo Børs commencing on Monday 3 June. The
IPO consisted of the sale of 11,840,000 new shares, representing 42.5% of the 27,860,400 shares
outstanding after the IPO. The price in the IPO was set at NOK 31.25 per share, corresponding to
a market value of Ultimovacs after the IPO of approximately NOK 870 million.
Stabilisation of the IPO will be carried out through a reverse over-allotment option (Brownshoe), in
which Ultimovacs’ shareholders Canica AS, Gjelsten Holding AS, Helene Sundt AS and CGS
Holding AS will purchase shares that have been purchased as part of the stabilisation activities.
The net proceeds will be used to fund 1) a Proof of Concept Phase II study for the cancer vaccine
UV1 in malignant melanoma and related activities, 2) preclinical development of a second product
candidate UV2 and 3) general and administrative activities.
The IPO attracted strong interest from domestic and international institutional investors, including
healthcare specialist funds, as well as retail subscribers in Norway – Ultimovacs will have more
than 1,500 shareholders following the IPO.